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Development of alternative methods for the determination of 
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Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
Three methods are proposed for the quantitative determination of raloxifene hydrochloride in 
pharmaceutical dosage form: ultraviolet method (UV) high performance liquid chromatography (HPLC) 
and micellar capillary electrophoresis (MEKC). These methods were developed and validated and showed 
good linearity, precision and accuracy. Also they demonstrated to be specific and robust. The HPLC 
and MEKC methods were tested in regards to be stability indicating methods and they showed to have 
this attribute. The UV method used methanol as solvent and optimal wavelength at 284 nm, obeying 
Lambert-Beer law in these conditions. The chromatographic conditions for the HPLC method included: 
NST column C18 (250 x 4.6 mm x 5 µm), mobile phase water:acetonitrile:triethylamine (67:33:0,3 v/v), 
pH 3.5, flow rate 1.0 mL min-1, injection volume 20.0 µl, UV detection 287 nm and analysis temperature 
30 °C. The MEKC method was performed on a fused-silica capillary (40 cm effective length x 50 µm 
i.d.) using as background electrolyte 35.0 mmol L-1 borate buffer and 50.0 mmol L-1 anionic detergent 
sodium dodecyl sulfate (SDS) at pH 8.8. The capillary temperature was 32°C, applied voltage 25 kV, 
UV detection at 280 nm and injection was perfomed at 45 mBar for 4 s, hydrodimanic mode. In this 
MEKC method, potassium diclofenac (200.0 µg mL-1) was used as internal standard. All these methods 
were statistically analyzed and demonstrated to be equivalent for quantitative analysis of RLX in tablets 
and were successfully applied for the determination of the drug.
Uniterms: Raloxifene/determination in tablets. High performance liquid chromatography/quantitative 
analysis. UV spectrophotometric method/quantitative analysis. Micellar capillary electrophoresis/
quantitative analysis. Stability-indicating methods.
Três métodos são propostos para a quantificação de cloridrato de raloxifeno em sua forma farmacêutica 
de comprimidos: espectrofotometria no ultravioleta (UV), cromatografia líquida de alta eficiência 
(HPLC) e eletroforese capilar micelar (MEKC). Estes métodos desenvolvidos e validados demonstraram 
linearidade, precisão e exatidão. Também foram específicos e robustos. Os métodos HPLC e MEKC 
foram desenvolvidos para indicar a estabilidade do fármaco e demonstraram ter este atributo. O método 
UV usou metanol como solvente e comprimento de onda de 284nm, obedecendo a Lei de Lambert-Beer 
nestas condições. Os parâmetros cromatográficos para o método HPLC foram: coluna NST C18 (250 x 
4,6 mm x 5 µm), fase móvel composta de água:acetonitrila:trietilamina (67:33:0,3 v/v), pH 3,5, vazão da 
fase móvel de 1,0 mL min-1, volume de injeção de 20 µl, detecção no comprimento de onda de 287 nm 
e temperatura de análise de 30°C. O método MEKC foi realizado utilizando capilar de sílica fundida 
(40 cm de comprimento efetivo x 50 µm de diâmetro interno) usando como fase móvel solução tampão 
borato 35.0 mmol L-1 e solução de dodecil sulfato de sódio (SDS) 50.0 mmol L-1 pH 8,8. A temperatura 
de análise foi de 32 °C, com voltagem aplicada de 25 kV, detecção no comprimento de onda de 280 nm 
e injeção da amostra realizada a 45 mBar por 4 s em modo hidrodinâmico. Para este método MEKC, 
foi utilizado diclofenaco de potássio (200.0 µg mL-1) como padrão interno. Todos os métodos foram 
analisados estatisticamente e demostraram ser equivalentes para a análise quantitativa de raloxifeno em 
comprimidos e foram aplicados com sucesso na determinação do fármaco.
Unitermos: Raloxifeno/determinação em comprimidos. Cromatografia líquida de alta eficiência/análise 
quantitativa. Espectrofotometria no ultravioleta/análise quantitativa. Eletroforese capilar micelar/análise 
quantitativa. Método indicador de estabilidade
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INTRODUCTION
Raloxifene (RLX) chemically [6-hydroxy-2-(4-
hydroxyphenyl)-benzotiophen-3-yl]-[4-[2-(1-piperidyl)
ethoxy]phenyl]-metadon (Figure 1), is a selective 
oestrogen-receptor modulator (SERM) that has been 
approved for use in the prevention and treatment of 
osteoporosis in postmenopausal women. A SERM interacts 
with oestrogen receptors, functioning as an agonist in some 
tissues (bone and cardiovascular system) and as antagonist 
in other tissues (mammary tissue and uterus) (Katzung, 
2006; Rang et al., 2006). Recently, raloxifene has been 
also approved by FDA for the prevention of invasive 
breast cancer. It was developed by Ely Lilly Company 
and marketed as Evista® in form of tablets of 60.0 mg. 
It is generally well tolerated, but it has as most common 
adverse effects hot flashes and leg cramps. A serious 
adverse effect is venous thromboembolism (ANVISA, 
2012; Brunton et al., 2010; NCI, 2012).
The literature survey reveals several methods 
for  the  determinat ion  of  RLX comprehending 
liquid chromatographic methods (HPLC) either for 
pharmaceutical dosage forms or biological fluids and 
spectrophotometric methods. The HPLC methods 
were mostly with UV detection but also detection by 
mass spectrometry. All these HPLC methods require 
use of buffer solutions as mobile phase in isocractic or 
gradient way. It has been also described a capillary zone 
electrophoresis method applied to quantify RLX in human 
plasma and tablets. The spectrophotometric methods were 
in the ultraviolet region (UV) or visible region (VIS) 
and required complex formation for the measurements. 
All these reported methods can be laborious and time 
consuming and some require special derivatization 
reactions. These reported methods are summarized at 
Table I.
The aim of this study was to develop simple, rapid 
and easy to execute procedures for routine analysis of 
raloxifene hydrochloride in dosage forms. The developed 
analytical methods were micellar capillary electrophoresis 
(MEKC), high performance liquid chromatography 
(HPLC), widely used in routine analysis, using water 
instead of buffer solution as mobile phase, and a direct 
UV spectrophotometric method. A statistical comparison 
between these three developed methods was made. 
Degradation studies also were done to find the inherent 
stability of the active substance.
MATERIAL AND METHODS
Chemicals
Standard bulk drug samples of RLX and potassium 
diclofenac were acquired from Pharma Nostra 
Distribuidora LTDA. The pharmaceutical dosage form 
Evista® containing 60.0 mg of RLX was furnished by 
INCT-IF. All reagents were of analytical grade: HPLC 
methanol (Honeywell International Inc, Muskegon, USA), 
HPLC acetonitrile (Tedia, Fairfield, USA), boric acid 
(Merck, São Paulo, Brazil), sodium dodecylsulfate (Synth, 
São Paulo, Brazil) and triethylamine (Vetec Química Fina 
Ltda, Rio de Janeiro, Brazil).
The HPLC mobile phase was degassed by 
ultrasonication (Unique, São Paulo, Brazil). Running 
electrolytes and samples were filtered through 0.45 µm 
filters (Macherey-Nagel, Düren, Germany).
Apparatus and conditions
HPLC method was performed in a Shimadzu 
liquid chromatograph (Tokyo, Japan) equipped with a 
LC-20AT Prominance pump, UV/VIS SPD-10AVAvp 
detector, BUS MODULE CBM-20A communicator, 
SIL-20A autosampler and CTO-20A column oven. The 
data acquisition and analysis were made by CLASS-VP 
software (version 6.1). The stationary phase was a RP C18 
NST column (250 x 4.6 mm id, particle size 5 µm) and the 
mobile phase consisted of water-acetonitrile-triethylamine 
(67:33:0.3 v/v) pH 3.5 (adjusted with o-phosphoric acid 
20%). Other chromatographic conditions included mobile 
phase flow rate of 1,0 mL min-1, injection volume of 
20.0 µL and analysis temperature (30°C). The absorption 
wavelengths were set at 287 nm to detect the components.
A Agilent3D CE equipment (Agilent Technologies, 
Germany) equipped with autosampler, diode array 
detector, temperature controlling system (4-60 °C), and 
power supply able to deliver up to 30 kV was used for the 
CE measurements. CE ChemStation software was used 
for instrument control, data acquisition and analysis. The 
detector wavelength was set at 280 nm. The separations 
were performed in a fused-silica uncoated capillary 
(48.5 cm x 50 µm id, Agilent, Germany) with temperature 
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FIGURE 1 - Chemical structure of raloxifene hydrochloride.
Development of alternative methods for the determination of raloxifene hydrochloride in tablet dosage form 351
TABLE I - Proposed methods for quantification of RLX by LC, CE and spectrophotometry
LC methods
UV detection – impurities Jancic-Stojanovic et al., 2011 
UV detection – tablets and raw material Kumar et al., 2011 
UV detection – tablets and raw material Suneetha, Lakshman, 2010 
UV detection – tablets and raw material Basavaiah, Kumar, Tharpa, 2008a 
UV and MS detection – human plasma Trontelj et al., 2007
UV detection – rat plasma and tissue Yang et al., 2007
UV detection – rat tissue Yang, He, Zhang, 2007
UV detection – tablets Pavithra, Sivasubramania, 2006a 
UV detection – tablets Reddy et al., 2006
UV detection – tablets Trontelj et al., 2005 
Spectrophotometric methods
VIS region – tablets Kalyanaramu, Raghubabu, 2011 
VIS region – tablets Kalyanaramu et al., 2011 
VIS region – tablets and raw material Basavaiah, Tharpa, Kumar, 2009 
UV and VIS region – tablets and raw material Pavithra, Sivasubramanian, 2006b 
VIS region – tablets and raw material Basavaiah, Kumar, Tharpa, 2008b
VIS region – tablets and raw material Annapurna, Rao, Kumar, 2007 
VIS region – tablets and raw material Dharuman et al., 2004 
VIS region – tablets Liu, 2002
EC method
UV detection – tablets and human plasma Perez-Ruiz et al., 2004 
UV – ultraviolet; VIS – visible; MS – mass spectrometry
controled at 32 °C. The voltage was set at 25 kV and the 
samples were pressure-injected at 45 mbar for 4 s. The 
background electrolyte (BGE) consisted of 35.0 mmol L-1 
borate buffer, and 50.0 mmol L-1 anionic detergent sodium 
dodecyl sulfate (SDS) adjusted to pH 8.8 with sodium 
hydroxide 0.1 mol L-1. The capillary was activated with 
sodium hydroxide 1.0 mol L-1. A daily conditioning 
of the capillary was performed consisting of washing 
with sodium hydroxide 1.0 mol L-1 (20 min), ultrapure 
water (15 min) and BGE (15 min). Also, between the 
sample injections, the capillary was flushed with sodium 
hydroxide 0.1 mol L-1 (3 min), ultrapure water (1 min) and 
BGE (2 min). Diclofenac potassium was used as internal 
standard.
The UV absorbance was measured at 284 nm using 
methanol as solvent in a Shimadzu UV-1601PC (Tokyo, 
Japan) equipment. The same solvent was used as blank. 
The UV analyses were made using 1 cm quartz cells.
Samples and standard solutions preparations
HPLC method
Twenty tablets of Evista® were weighed and 
average weight was calculated. The tablets were crashed 
and stock solution was prepared weighing a quantity 
equivalent to 10.0 mg of raloxifene and transferred to a 
100.0 mL volumetric flask (100.0 µg mL-1) dissolving with 
water:acetonitrile (60:40 v/v). Working solutions were 
prepared by diluting appropriately 1.0 mL of the stock 
solution into a 10.0 mL volumetric flask completing the 
volume with mobile phase (10.0 µg mL-1).
Stock solution of raloxifene reference substance 
(RLX RS) was prepared weighing 10.0 mg of RLX RS 
and dissolving in water:acetonitrile (60:40 v/v). Aliquot 
of this solution was diluted to give a final concentration 
of 10.0 µg mL-1.
These stock solutions were stored at room 
temperature, protected from light and the working 
solutions were daily prepared and filtered before injection.
MEKC method
Standard stock solution was prepared in methanol 
weighing 25.0 mg of RLX RS and transferring into a 
25.0 mL volumetric flask (1000.0 µg mL-1). Working 
solution was prepared transferring an aliquot which was 
diluted in the BGE to a final concentration of 80.0 µg mL-1.
From the same tablet powder utilized for the 
HPLC method, a quantity equivalent to 25.0 mg of RLX 
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was weighed and dissolved in methanol in a 25.0 mL 
volumetric flask (1000.0 µg mL-1). From this solution, 
0.8 mL was transferred into a 10.0 mL volumetric flask 
and volume completed with BGE (80.0 µg mL-1).
A stock solution of the internal standard used in this 
method was prepared weighing 20.0 mg of potassium 
diclofenac RS and transferring to a 20.0 mL volumetric 
flask diluting with methanol. From this solution 2.0 mL 
were transferred into the working solution of standard 
and sample, giving a final concentration of 200.0 µg mL-1.
These stock solutions were stored at room 
temperature, protected from light and the working 
solutions were daily prepared and filtered before injection.
UV method
A quantity of 15.0 mg of RLX RS was weighed and 
transferred into 100.0 mL volumetric flask and dissolved 
with methanol to prepare the standard stock solution 
(150.0 µg mL-1). From this solution, an aliquot of 1.0 mL 
was transferred into a 20.0 mL volumetric and volume 
completed with the same solvent.
From the same tablet powder used to both MEKC 
and HPLC methods, a quantity equivalent to 15.0 mg 
of RLX was weighed and dissolved with methanol to a 
concentration of 150.0 µg mL-1 (stock solution). Working 
solution was prepared transferring aliquot from the stock 
solution to a final concentration of 7.5 µg mL-1 with 
methanol.
Method validation
The developed methods were validated according 
to the International Conference on Harmonization (ICH) 
guidelines (2003, 2005) by determination of the following 
parameters:
Specificity
The methods specificity was investigated by 
observing interferences from RLX tablets excipients. 
Their concentration was based on information furnished 
by Handbook of Pharmaceutical Excipients (Rowe, 2009) 
and calculated in relation of its medium weight. The 
analyses of the placebo solutions were compared with 
the results of the tablet solutions to verify the probable 
interference of the excipients in the RLX determination.
Linearity
The linearity of the methods was evaluated by 
plotting calibration curves in the range of 3.0-12.0 µg mL-1 
for the UV method, 4.0-16.0 µg mL-1 for the HPLC 
method with seven different concentrations for each one, 
and 40.0-120.0 µg mL-1 for the MEKC method, with five 
concentrations in this range. All the analyses were made 
in triplicate every day, during three consecutive days. The 
values of the peak areas for LC and MEKC methods and 
UV absorbance were computed and analyzed by linear 
regression analysis.
Precision
Precision studies were done in terms of repeatability 
(intra-day precision) and intermediate precision (inter-
day precision). The data precision was expressed in 
percent relative standard deviation (RSD%) of a series of 
measurements. Repeatability was analyzed through the 
determination of six samples containing an equivalent 
amount of 10.0 µg mL-1 RLX from the tablets powder for 
the LC method and an equivalent amount of 80.0 µg mL-1 
RLX from the tablets powder and 200.0 µg mL-1 of 
potassium diclofenac RS for the MEKC method. For 
the UV method, samples of RLX tablets powder in 
three different concentrations (6.0, 7.5 and 9.0 µg mL-1) 
in triplicate were analyzed and intra-day precision 
determined. All the analyses were made in triplicate in the 
same day. Inter-day precision was studied by comparing 
the results on three different days.
Accuracy
The accuracy of the methods was evaluated by 
performing recovery studies. A solution of the RLX 
tablets powder with fix concentration was prepared and 
aliquots in three different concentrations (80.0, 100.0 and 
120.0%) of RLX RS solution were added to the RLX tablet 
solutions. These solutions were analyzed in triplicate and 
concentrations and recoveries were calculated against the 
added concentrations.
Robustness
Robustness of the methods was evaluated by 
examining the influence of small variations in the 
analytical parameters of the method. The method should 
be robust enough with respect to all critical parameters 
so as to allow routine laboratory use. For the HPLC 
method, the changed parameters were: temperature, flow 
rate, proportion of the mobile phase, pH of the mobile 
phase and a different column. The effects of changed 
parameters were evaluated based on the RSD% values 
obtained among the injections and values of recovery 
considering the determination value founded as 100%. 
For the MEKC methods, the changed parameters were 
combined in a factorial design of 24 calculating and 
analyzing the influence of the changes by Minitab®15 
software. The made variations were: concentration of boric 
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acid, concentration of surfactant, pH of the buffer solution, 
temperature of the analysis and applied voltage. For the 
UV method the robustness was not evaluated.
(a) LOD and LOQ
The LOD and LOQ values were mathematically 
determined through the calibration curve. The factors 
(3.3 and 10) were multiplied by the ratio from residual 
standard deviation and slope, according to the ICH 
guideline (2005).
(b) Degradation studies
The stability-indicating capability of the HPLC and 
MEKC methods was determined by performing forced 
degradation of RLX solution under acid/basic hydrolysis, 
oxidative, thermal and photolytic stress conditions to 
evaluate the interference of degradation products in the 
determination of the drug. Acid and basic hydrolysis 
were performed by subjecting RLX solution to a 24 h 
exposition to hydrochloric acid 1.0 mol L-1 and sodium 
hydroxide 1.0 µg mL-1, respectively, in room temperature 
and protected from light. The oxidation degradation was 
induced by exposing the RLX solution to 3.0% H2O2 
for 24 h in room temperature, protected from light. For 
thermal degradation, the RLX solution in methanol was 
exposed at 80 °C in an oven for 24 h. For photolytic 
stress study, the sample in methanol was placed in quartz 
cuvettes in a light chamber and exposed to UV-A radiation 
(352 nm) for 24 h. Blank samples were also subjected to 
the same treatment of the degradation studies and control 
sample was prepared and stored protected from light. The 
same treatment was given to the solutions of both methods 
and samples were prepared and analyzed according to the 
respective method. The specificity of the methods was 
established by determining the peak purity in the degraded 
samples using PDA detector.
RESULTS AND DISCUSSION
Method development
Chromatographic parameters for the HPLC method 
were optimized to achieve optimal conditions. Effect of 
the mobile phase composition was studied by varying 
the proportions of the components (water, acetonitrile 
and triethylamine) until the proposed composition of 
67:33:0,3 v/v based on peak parameters such as symmetry, 
theoretical plates and capacity factor. The cost and 
preparation and so the effect on the equipment were also 
considered, therefore it was used as mobile phase water 
instead of buffer solution that it is as efficient as buffer 
solutions to perform the chromatographic separations. The 
retention time obtained was considered suitable and has 
demonstrated good sensitivity for the determination of the 
drug proposed. A good separation, with symmetrical peaks, 
was obtained using a RP C18 column (250 × 4.6 mm) 
and the mobile phase chosen above. The effect of the 
temperature was investigated and the optimal temperature 
was 30 °C; optimum wavelength for quantification was 
287 nm. The system suitability of the chromatographic 
system was performed during the development of the 
method and peak asymmetry, theoretical plate number 
and RSD of peak areas were determined. For the system 
suitability, it was found an asymmetry of < 1.5, theoretical 
plate number of > 8000 and RSD of peak area of < 1.0%. 
A typical chromatogram of RLX with retention time of 
7.6 min is shown in figure 2-A.
For the electrophoretic conditions the influence of 
pH, buffer concentration and electric field on the migration 
time and selectivity was investigated. The optimization of 
the method was performed first testing some electrolyte 
solutions alone and with addition of surfactant SDS. 
Also the BGE pH was evaluated in the range of 4.5-6.0 
for BGE electrolyte solutions alone and 8.0-9.0 for the 
solutions added with surfactant. The BGE which had 
the best results with good separation performance was 
35.0 mmol L-1 boric acid and 50.0 mmol L-1 SDS. The 
BGE pH 8.8 was selected since at this pH the resolution 
increased, while analysis time decreased. This pH 8.8 
selected BGE obtained the best parameters, such as peak 
symmetry (about 1.0) and resolution between the peaks. 
The buffer concentrations varied from 20.0-50.0 mmol L-1 
for boric acid and 20.0-60.0 mmol L-1 for SDS keeping the 
pH constant at 8.8. The optimum conditions were found 
to be 35.0 mmol L-1 for boric acid and 50.0 mmol L-1 for 
SDS, since above these concentrations the migration time 
increases; in these conditions suitable peak parameters 
were also generated and good efficiency was achieved. The 
effect of the voltage applied was investigated and better 
separation and migration time with acceptable current 
(about 30.0 µA) was established with 25 kV. The capillary 
temperature was evaluated and 32°C was chosen, because 
with the same the analysis time decreased. Due to increase 
of peak width and deformed shape above 45 mBar and 4 s 
the sample solutions were hydrodynamically injected at 
this condition. The optimum wavelength was set on 280 nm 
for quantification of RLX. An internal standard (IS) was 
used to compensate injection errors and fluctuations of 
migration time. Several drugs were tested and diclofenac 
potassium (DI) demonstrated to be suitable for the analysis 
with good absorption at the used wavelength with good 
peak resolution. The electropherogram of RLX and DI RS 
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with migration time of 3.6 min (DI) and 6.9 min (RLX), 
respectively is shown in Figure 2-B.
For the UV method conditions, RLX demonstrated 
to be completely soluble in methanol; it was selected as 
solvent, because provided the highest UV absorbance. The 
optimum wavelength was set on 284 nm. These conditions 
showed to obey Beer-Lambert’s law. A typical spectrum 
of RLX is shown in Figure 2-C.
Method validation
Interference from the formulation excipients 
was evaluated for all the methods. The excipients 
included povidone, polysorbate 80, lactose 70%, 
crospovidone, magnesium stearate, titanium dioxide, 
hydroxypropylmethylcellulose, polyethylene glycol and 
propylene glycol. No interference was found in any of 
the proposed methods. The specificity, for the MEKC and 
HPLC methods, was established through a determination 
of the purity peak of the analyte using diode array detector. 
The peaks were free from any coeluting peak. For the UV 
method, it was observed in the comparison of the spectrum 
of the drug solution and the solution containing excipients 
of the formulation that no interference occurred.
To check the linearity, a standard curve was 
constructed and the statistical parameters of the analytical 
curve for MEKC, HPLC and UV methods are presented 
in table 2. The calibration curves proved to be linear in 
concentration range of 40.0-120.0 µg mL-1 for MEKC, 
4.0-16.0 µg mL-1 for HPLC and 3.0-12.0 µg mL-1. All 
FIGURE 2 - RLX solutions: (A) typical UV spectrum of RLX in 7.5 µg mL-1, (B) typical chromatogram of RLX in 10.0 µg mL-1, 
chromatographic conditions - NST column C18 (250 x 4.6 mm x 5µm), mobile phase of water:acetonitrile:triethylamine 
(67:33:0,3 v/v), flow rate 1.0 mL min-1, injection volume 20.0 µl, UV detection 287 nm and analysis temperature 30 °C, (C) typical 
electropherogram of RLX and DI as internal standard, 80.0 µg mL-1 and 200.0 µg mL-1 respectively, electrophoretic conditions – BGE 
of boric acid 35.0 mmol L-1 + SDS 50.0 mmol L-1 pH 8.8, fused-silica capillary columm (40 cm length x 50 µm i.d.), hydrodynamic 
injection time of 4s at pressure 45 mBar, separation voltage 25 kV and column temperature 32 °C with detection at 280 nm.
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TABLE II - Linearity and precision of UV, HPLC and CE methods for quantification of hydrochloride raloxifene in tablets
Parameters UV HPLC CE
Linearity 3.0-12.0 µg mL-1 4.0-16.0 µg mL-1 40.0-120.0 µg mL-1
Intercept 0.0099 11091 0.0443
Slope 0.0672 74555 0.0156
Correlation coefficient 0.9994 0.9992 0.9991
LOD 0.1 µg mL-1 0.5 µg mL-1 12.1 µg mL-1
LOQ 0.3 µg mL-1 1.5 µg mL-1 36.6 µg mL-1
Precision
Day I II III I II III I II III
Intraday* 101.09 100.29 102.35 99.24 99.39 101.69 99.07 99.51 101.07
RSD% 1.27 0.94 1.12 0.61 0.64 0.72 2.05 1.94 1.83
Interday ** 101.57 100.11 99.84
RSD % 1.12 1.37 2.03
HPLC and CE - n = 6; ** HPLC and CE - n = 18; UV - n = 9 ;UV - n= 27
TABLE III - Accuracy data (recovery studies) of UV, HPLC and MEKC methods for quantification of hydrochloride raloxifene in 
tablets
Amount added (µg mL-1) Amount found (µg mL-1)* Recovery (%)* RSD %
UV HPLC CE UV HPLC CE UV HPLC CE UV HPLC CE
2.0 3.42 21.06 2.03 3.41 21.35 100.87 99.91 100.86 0.71 1.50 2.83
3.5 5.70 42.03 3.48 5.67 39.18 99.14 99.50 97.11 1.08 0.38 3.38
5.0 7.98 63.05 5.04 7.97 58.69 100.34 99.87 97.00 0.59 0.18 3.30
*Average of three determinations
methods showed good linearity with correlation coefficient 
(r) greater than 0.999 and linear regression was verified by 
means of analysis of variance (ANOVA) and demonstrated 
no deviation from linearity. All plots were based on analyte 
concentrations versus UV absorbance (UV), peak area 
response ratios (HPLC) and ratios of standard drug peak 
areas to internal standard peak areas (MEKC). The LOD 
and LOQ were calculated and estimated to be 0.5 µg mL-1 
and 1.5 µg mL-1, respectively, for the HPLC method, 
12.1 µg mL-1 and 36.6 µg mL-1 for the MEKC method 
and 0.1 µg mL-1 and 0.3 µg mL-1 for the UV method. 
MEKC method obtained higher values for LOD and LOQ, 
nevertheless, suitable sensitivity for the method. UV 
and HPLC methods demonstrated great sensitivity with 
low LOD and LOQ values. Among the methods, the UV 
provided the lowest LOD and LOQ for the analysis of RLX.
Repeatability (intra-day) and intermediate (inter-
day) precision for the three methods were determined and 
they were expressed as the RSD% of the results that are 
summarized in Table 2. In most cases, the variability of 
the results was low with RSD% of UV and HPLC method 
was less than 1.5% for repeatability and intermediate 
precision. For the MEKC method, the RSD% obtained was 
within 2.0% for both intra e inter-precision. RSD values 
found for all the methods were within the acceptable 
range indicating that the methods proposed have good 
repeatability and low inter-day variability.
Recovery studies were performed using standard 
addition technique covering 80-120% (three levels 
concentration) of the nominal sample concentration to 
determine the accuracy of the methods and the results are 
presented in Table III. The RLX accuracy results showed % 
recoveries ranging from 99.14-100.76% for the UV method 
with RSD% lower than 1.5% and for HPLC method ranged 
from 99.50-99.91 with RSD% within 1.5%. These values 
obtained from the recovery results showed good accuracy 
for the UV and HPLC methods. For MEKC method, the 
recovery varied from 97.0-100.87% and showed values of 
RSD up to 3.38%, even though it varied more than the other 
methods still showed good accuracy.
The robustness of MEKC and HPLC methods was 
evaluated and results are presented in Table IV for the 
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HPLC method and in Figure 3 for the MEKC method. For 
the HPLC method it was varied to determine the robustness 
chromatographic parameter such as flow, proportion of the 
mobile phase (water and acetonitrile), temperature of the 
column, pH of the mobile phase and different brand column. 
In the MEKC method, the electrophorectic conditions 
changed were concentration of boric acid, concentration of 
the surfactant used, pH of the buffer solution, temperature 
of analysis and applied voltage. For both methods only 
non-significant changes in migration time and peak area 
ratios are observed. All the recovery percentages obtained 
from the parameter changes varied less than 5.0% and 
the RSD obtained from the injections was less than 1.0% 
indicating the robustness of the method. The influence on 
the analysis conditions of MEKC method was determined 
by factorial design and is presented in a Pareto Chart. As the 
Pareto Chart shows, there was non-significant influence of 
all parameter changes in the quantification of RLX; so the 
method was considered robust.
The specificity and stability-indicating capability of 
the MEKC and HPLC methods were evaluated by analysis 
of samples submitted to stress testing of RLX under 
different conditions. The proposed methods yielded to 
achieve peak purity to guarantee selectivity of the methods. 
No stability-indicating methods for determination of RLX 
have been reported. The results showed that when RLX 
was submitted to acidic condition there was a significant 
area decrease higher than 50.0% for both methods (Figure 
4-A and Figure 5-A) and no peaks of degradation products 
were observed. For the oxidative conditions there was 
around 50.0% and 10.0% of area decrease for HPLC (Figure 
4-C) and MEKC method (Figure 5-C), respectively. In the 
chromatogram of the HPLC method (Figure 4-C), peaks of 
degradation products were observed at 5.9 min and at 8.1 
min, also at about 3.0 min. Another condition in which peak 
of degradation product was observed, was the photolytic 
condition, where the additional peak appeared in the 
chromatogram at about 8.0 min (Figure4-D). No significant 
area decrease occurred in this condition, as well as for the 
basic (Figure 4-B) and thermal conditions (Figure 4-E), 
corresponding to less than 5.0%. In the two last conditions 
no additional peaks were observed in the chromatograms. 
In the electropherograms of MEKC method (Figure 5), no 
additional peaks of degradation products were observed in 
any of the stress conditions to which RLX was submitted. It 
was observed the sensibility of MEKC method is probably 
less than the HPLC method, since it was necessary to work 
with higher concentrations. These samples were considered 
suitable for the methods development, since degradations 
products could be observed. The peak purity indexes 
confirmed that for both methods there was no interference 
of any other substances at the RLX and degradations 
products peaks; also no interference in the DI RS peak in 
MEKC method, showing that they were 99.9% pure in all 
circumstances. It was verified that the RLX peak presents 
appropriate resolution and selectivity in relation to the 
degradation products formed. Analyzed by diode-array 
detector, the degradation products detected in the HPLC 
method had the same spectrum as RLX. This means that 
probably the structure of the same is very similar with the 
RLX structure.
According to these results, these proposed methods 
(HPLC and MEKC) can be considered stability-indicating, 
since they succeeded in separate and evaluate qualitatively 
and quantitatively the RLX in presence of degradation 
TABLE IV - Robustness of HPLC method
Parameter RSD* Recovery (%)**
Proposed method 0.25
Different column 0.44 100.1
Temperature 29°C 0.04 100.6
Temperature 31°C 0.07 100.2
Flow 0,95ml/min 0.07 100.5
Flow 1,05ml/min 0.10 100.4
Water:acetonitrile (66:34) 0.08 100.3
Water:acetonitrile (68:32) 0.10 100.4
pH 3.4 0.11 100.2
pH 3.6 0.05 100.1
* between three injections; ** amount obtained with proposed 
method was considered 100.0%
FIGURE 3 - Robustness of MEKC method (Pareto chart of 
the effects – []tampão =concentration of boric acid, []sds = 
concentration of the surfactant, pH = pH of the buffer solution, 
temp = temperature of the analysis, volt = applied voltage of 
the analysis).
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FIGURE 4 - HPLC Chromatograms of RLX solutions submitted to forced degradation for 24 h (A) acidic hydrolysis (HCl 
1.0 mol L-1), (B) basic hydrolysis (NaOH 1.0 mol L-1), (C) oxidative stress (H2O2 3.0%), (D) photolytic stress (UV 352nm) and 
(E) heat stress (80 °C). Chromatographic conditions: NST column C18 (250 x 4.6 mm x 5µm), mobile phase of water:acetonitrile:tr
iethylamine (67:33:0,3 v/v), flow rate 1.0 mL min-1, injection volume 20.0 µl, UV detection 287 nm and analysis temperature 30 °C.
products formed. Thus, the degradation studies showed 
that this drug is susceptible to acidic hydrolysis and 
oxidation and apparently not susceptible to basic 
hydrolysis, thermal and photolytic degradation.
Comparison between UV, HPLC and MEKC 
methods
The proposed methods were compared statistically 
by ANOVA, using F-test. The results (Table V) showed 
that there was no significant difference between the 
experimental values obtained for the tablets by the three 
methods. The calculated F-value (0.99163) was found 
to be less than the critical F-value (3.17879) at 5.0% 
of significance level. This result shows that the three 
methods are equivalent for the quantitative determination 
of raloxifene hydrochloride in formulations.
Determination of RLX in tablets
The developed methods were applied for the 
analysis of raloxifene hydrochloride in tablets. The results 
F. R. Salazar, C. F. Codevilla, L. Meneghini, A. M. Bergold358
FIGURE 5 - MEKC electropherograms of RLX solutions submitted to forced degradation for 24 h (A) acidic hydrolysis (HCl 
1.0 mol L-1), (B) basic hydrolysis (NaOH 1.0 mol L-1), (C) oxidative stress (H2O2 3.0%), (D) photolytic stress (UV 352 nm) and 
(E) heat stress (80°C). Electrophoretic conditions: BGE of boric acid 35.0 mmol L-1 + SDS 50.0 mmol L-1 pH 8.8, fused-silica 
capillary column (40.0 cm length x 50 µm i.d.), hydrodynamic injection time of 4 s at pressure 45 mBar, separation voltage 25 kV 
and column temperature 32 °C with detection at 280 nm.
TABLE V - Comparison between UV, HPLC and MEKC methods
UV HPLC CE
Average (%) 100.58 100.11 99.88
RSD 1.09 1.31 2.03
ANOVA (p = 0.05) Fcal = 0.99163 < Fcrit = 3.17879
are presented in Table VI and it showed that the amount 
founded for UV method was 59.76 mg (RSD 0.2), 59.41 
mg for the HPLC (RSD 0.15) and 59.87 mg for the 
MEKC method (RSD 0.17). The tablets have 60.0 mg of 
label claim. The results for the three methods are similar 
with low RSD and so demonstrated that all the proposed 
methods showed to be applicable for the determination of 
RLX in tablets.
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TABLE VI - Percent label amounts of hydrochloride raloxifene in tablets
Amount found (mg/tablet) RSD %
Labeled amount (mg/tablet) UV HPLC MEKC UV HPLC MEKC
60.0 59.76 59.41 59.87 0.20 0.15 1.17
CONCLUSIONS
The proposed UV, HPLC and MEKC methods are 
simple, precise, accurate and easy to execute. All methods 
used simple reagents with minimal sample preparation 
procedures. The HPLC and MEKC methods can be 
considered stability indicating, due to the capability to 
detect RLX in presence of degradation products, therefore 
they were recommended for determination of the drug 
and degradation products in stability study samples, 
especially the HPLC method. All the methods were 
successfully applied for quantitative determination of RLX 
in pharmaceutical dosage form and suitable for routine 
analysis of drug in formulation.
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